Trouble Brewing Behind Medpace’s Sweet Promises

Back in February 2026, Medpace shocked investors by missing its own book-to-bill target. Instead of reaching the expected 1. 15x ratio, the company reported just 1. 04x. That might sound like a small difference, but in the financial world, it was a big deal. The news triggered a sharp 15. 9% drop in